左西孟旦注射液联合培哚普利叔丁胺片治疗充血性心力衰竭患者的临床研究  

Clinical trial of levosimendan injection combined with perindopril tert-butylamine tablets in the treatment of patients with congestive heart failure

作　　者：戴朝博[1] 吴婷玉[1] DAI Chao-bo;WU Ting-yu(Department of Gerontology,Wuhan No.1 Hospital,Wuhan 430022,Hubei Province,China)

机构地区：[1]武汉市第一医院老年病科,湖北武汉430022

出　　处：《中国临床药理学杂志》2020年第19期2968-2971,共4页The Chinese Journal of Clinical Pharmacology

基　　金：湖北省卫生和计划生育委员会科研课题资助项目(WJ2017F012)。

摘　　要：目的观察左西孟旦注射液联合培哚普利叔丁胺片治疗充血性心力衰竭(CHF)患者的临床疗效及安全性。方法将96例CHF患者随机分为对照组48例和试验组48例。对照组给予培哚普利叔丁胺每次2~4 mg,qd,口服;试验组在对照组治疗的基础上,给予左西孟旦注射液初始剂量12μg·kg^-1持续输注10 min,然后以0.1μg·kg^-1·min^-1静脉泵入1 h,再增加至0.2μg·kg^-1·min^-1,持续泵入23 h,第6天重复1次。2组患者均治疗14 d。比较2组患者的临床疗效,血管内皮功能和心功能,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为91.67%(44例/48例)和70.83%(34例/48例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的血清内皮素^-1分别为(40.15±14.40)和(53.29±16.27)μg·mL^-1,氨基末端脑钠肽前体分别为(2069.83±714.55)和(3124.05±894.51)pg·mL^-1,一氧化氮分别为(62.05±16.86)和(49.82±13.71)μg·mL^-1,左心室收缩末期内径分别为(49.52±3.52)和(54.07±3.60)mm,左心室舒张末期内径分别为(62.31±3.15)和(68.94±3.21)mm,左心室射血分数分别为(49.92±5.87)%和(44.05±5.26)%,差异均有统计学意义(均P<0.05)。试验组的药物不良反应主要有便秘和低血压,对照组的药物不良反应主要有低血压。试验组和对照组的总药物不良反应发生率分别为6.25%和4.17%,差异无统计学意义(P>0.05)。结论左西孟旦注射液联合培哚普利叔丁胺片治疗CHF患者的临床疗效确切,其能显著改善患者的血管内皮功能及心功能,且不增加药物不良反应的发生率。Objective To observe the clinical efficacy and safety of levosimendan injection combined with perindopril tert-butylamine tablets in the treatment of patients with congestive heart failure(CHF).Methods A total of 96 patients with CHF were randomly divided into control and treatment groups with 48 patients per group.The control group was treated with perindopril tert-butylamine 2-4 mg per time,qd,orally.The treatment group received the initial dose of levosimendan injection 12μg·kg^-1 for 10 min,and then pumped into vein at the speed of 0.1μg·kg^-1·min^-1 intravenously for 1 h,then increased the speed to 0.2μg·kg^-1·min^-1,continuously pumped for 23 h,and repeated once on the 6 th day,on the basis of control group.Two groups were treated for 14 d.The clinical efficacy,vascular endothelial function and cardiac function,and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of treatment and control groups were 91.67%(44 cases/48 cases)and 70.83%(34 cases/48 cases)with significant difference(P<0.05).After treatment,the main indexes of treatment and control groups were compared:serum levels of endothelin^-1 were(40.15±14.40)and(53.29±16.27)μg·mL^-1,N-terminal brain natriuretic peptide precursor were(2069.83±714.55)and(3124.05±894.51)pg·mL^-1,nitric oxide were(62.05±16.86)and(49.82±13.71)μg·mL^-1,left ventricular end systolic diameter were(49.52±3.52)and(54.07±3.60)mm,end-diastolic diameter of left ventricle were(62.31±3.15)and(68.94±3.21)mm,left ventricular ejection fraction were(49.92±5.87)%and(44.05±5.26)%,the differences were statistically significant(all P<0.05).The adverse drug reactions of treatment group were constipation and hypotension,while those in the control group were hypotension.The incidences of total adverse drug reactions in the treatment and control groups were 6.25%and 4.17%without significant difference(P>0.05).Conclusion Levosimendan injection combined with perindopril tert-butylamine tablets has a definitive clinical

关 键 词：左西孟旦注射液 培哚普利叔丁胺片 充血性心力衰竭 安全性评价 

分 类 号：R972[医药卫生—药品]